These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22397360)

  • 1. ENMD-2076 for hematological malignancies.
    How J; Yee K
    Expert Opin Investig Drugs; 2012 May; 21(5):717-32. PubMed ID: 22397360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Danusertib, an aurora kinase inhibitor.
    Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
    Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
    Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
    Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer.
    Kimura S
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1442-9. PubMed ID: 21154126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
    Yee KW; Chen HW; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T; Le LW; Arnott J; Bray MR; Sidor C; Minden MD
    Invest New Drugs; 2016 Oct; 34(5):614-24. PubMed ID: 27406088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.
    Zhang S; Farag SS
    Expert Opin Investig Drugs; 2011 Jul; 20(7):1015-28. PubMed ID: 21615212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S; Brullo C; Musumeci F; Botta M
    Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.
    Moore AS; Blagg J; Linardopoulos S; Pearson AD
    Leukemia; 2010 Apr; 24(4):671-8. PubMed ID: 20147976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.
    Fletcher GC; Brokx RD; Denny TA; Hembrough TA; Plum SM; Fogler WE; Sidor CF; Bray MR
    Mol Cancer Ther; 2011 Jan; 10(1):126-37. PubMed ID: 21177375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aurora kinase inhibitors as anti-cancer therapy.
    Lok W; Klein RQ; Saif MW
    Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New nucleoside analogs for patients with hematological malignancies.
    Robak T
    Expert Opin Investig Drugs; 2011 Mar; 20(3):343-59. PubMed ID: 21320002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1.
    Le Brazidec JY; Pasis A; Tam B; Boykin C; Black C; Wang D; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2070-4. PubMed ID: 22326168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
    Sankhala K; Giles FJ
    Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?
    Tsykunova G; Reikvam H; Ahmed AB; Nepstad I; Gjertsen BT; Bruserud Ø
    Expert Opin Investig Drugs; 2012 May; 21(5):587-603. PubMed ID: 22424119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora kinases: new targets for cancer therapy.
    Carvajal RD; Tse A; Schwartz GK
    Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of Aurora kinase inhibitors in haematological malignancies.
    Farag SS
    Br J Haematol; 2011 Dec; 155(5):561-79. PubMed ID: 21980926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
    Cheung CH; Sarvagalla S; Lee JY; Huang YC; Coumar MS
    Expert Opin Ther Pat; 2014 Sep; 24(9):1021-38. PubMed ID: 24965505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).
    Cheung CH; Coumar MS; Chang JY; Hsieh HP
    Expert Opin Ther Pat; 2011 Jun; 21(6):857-84. PubMed ID: 21591849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.